

	everolimus (n=33)	placebo (n=34)
Female:male	16:17 (48.5%)	17:17 (50.0%)
Age at first dose	31 days (26-34)	30 days (26-34)
Weight	14.77g (12-20)	15.07g (11-21)
WCC	11.84 ± 0.93 x10 ³ /uL	12.46 ± 0.59 x10 ³ /uL

Supplementary Table S1. Baseline characteristics of E_μ-Myc mice randomized to receive everolimus or placebo. Sex, average age and range, average weight and range and average white cell count with SEM of mice in the everolimus and placebo groups. There were no statistically significant differences between the groups at baseline.

Supplementary Table S2. Primer sequences (5' -3') used for qPCR expression analysis in B220+/- sorted cells.

Amplicon	Forward Sequence	Reverse Sequence
ICAM1	GGGACCACGGAGCCAATT	TTGCGGCCTGAGATCCA
IGFBP2	AGCATGGCCGGTACAACCT	CGCGCTGTCCGTTTCCAGA
IGFBP7	TCCCAACCCCTGTCCTCAT	CCGCTGAACTCCAGAGTGATC
IL6	CCACGGCCTTCCCTACTTC	TTGGGAGTGGTATCCTCTGTGA
ATG7	CCTGGCAGCCCACAGATG	CCCGAAAGCAGAGGACTTCA
BNIP3L	CCGCTGGCCTCAACAGTT	TTGCCATTGCTGCTGTTTCAT
p62	GGAGGCACCCCGAAACA	GCCCGTTGCAACCATCAC
WIP11	TGGCCGCTATCACCTTCAAC	CTTTTTCAGACGCGCTTGCT
GADD45	GCTGGTGACGAACCCACATT	CCCGGC AAAAACAATAAGTTG
p21	CCAGACATTGAGAGCCACAGG	GGTCGGACATCACCAGGATT
VIMENTIN	AGCTGCTAACTACCAGGACACTATTG	CGAAGGTGACGAGCCATCTC